# US 11,298,351 B2 · Bupropion as a modulator of drug activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,351 B2
- Document ID: US11298351B2
- Status: Granted
- Kind: B2
- Application number: 17/095,256
- Filed: 2020-11-11
- Published: 2021-03-04
- Granted: 2022-04-12
- Earliest claimed: 2013-11-05
- Assignees: Antecip Bioventures II LLC
- Applicants: Antecip Bioventures II LLC
- Inventors: Herriot Tabuteau
- Web page: https://patentgrep.com/patent/US11298351B2

## CPC

- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/15: Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) {; Imines (C—N=C)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/381: having five-membered rings
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

## Claims

### Claim 1

A method of treating major depression, comprising: orally administering a dosage form once a day or twice a day for at least 7 days, to a human being suffering from major depression, wherein bupropion and dextromethorphan are the only therapeutically active compounds in the dosage form, wherein the human being receives a daily dose of the bupropion that is about 200 mg to about 250 mg, wherein the daily dose of the bupropion is orally administered once a day or is a total of two twice daily doses of the bupropion, wherein the human being receives a daily dose of the dextromethorphan that is about 60 mg to about 100 mg, wherein the daily dose of the dextromethorphan is orally administered once a day or is a total of two twice daily doses of the dextromethorphan, wherein orally administering the bupropion in combination with the dextromethorphan results in the human being experiencing a therapeutic effect; wherein the dosage form provides immediate release of dextromethorphan and sustained release of bupropion; and wherein orally administering the dosage form is more effective in treating major depression than orally administering the same amount of the dextromethorphan alone for the same number of consecutive days.

### Claim 2 (depends on 1)

The method of claim 1, wherein after orally administering the dosage form, the human being experiences an improvement in a depressive symptom as compared to baseline.

### Claim 3 (depends on 1)

The method of claim 1, wherein orally administering the dosage form is more effective in treating major depression than orally administering a placebo.

### Claim 4 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered once daily.

### Claim 5 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered twice daily.

### Claim 6 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered for at least 14 consecutive days.

### Claim 7 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered for at least 30 consecutive days.

### Claim 8 (depends on 1)

The method of claim 1, wherein the dosage form has a weight ratio of the dextromethorphan to the bupropion that is about 0.3 to about 0.5.

### Claim 9 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered once a day for 1 day and twice a day thereafter.

### Claim 10 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered once a day for 2 days and twice a day thereafter.

### Claim 11 (depends on 1)

The method of claim 1, wherein the dosage form is orally administered once a day for 3 days and twice a day thereafter.

### Claim 12 (depends on 1)

The method of claim 1, wherein orally administering the dosage form is more effective than orally administering a placebo in reducing anxiety.